GI Dynamics Terminates Pivotal Endobarrier Trial Based On Safety Data

FDA and the company could not come up with a plan to continue the ENDO study for GI's device targeting obese patients with diabetes in response to higher-than-anticipated rates of liver infection. The company suggests, however, that development of the device will continue.